

Supplementary Tables 1-5 and Supplementary Figures 1-7

Supplementary Table 1. Clinical description and outcome of untreated control Lassa challenged NHPs

Subject No. ^(a)	Sex	MAb	Treatment Regimen (Days)	Clinical illness	Clinical and gross pathology
^b C-1 (1)	F	None	None	Fever (d7); depression (d10-14); lethargy (d12-14); loss of appetite (d5-14); mild rash (d14); tremors (d13-14); animal succumbed in am of d14	Granulocytosis (d3,5,14); lymphopenia (d7,10); thrombocytopenia (d5,7); hypoalbuminemia (d14); ALT > 5-fold ↑ (d14); AST > 2-fold ↑ (d7,10); AST > 10-fold ↑ (d14); ALP > 2-fold ↑ (d14); BUN > 2-fold ↑ (d14); CRP > 4-fold ↑ (d3,5); CRP > 6-fold ↑ (d10); CRP > 10-fold ↑ (d14)
C-2 (1)	M	None	None	Fever (d10); depression (d9-11); lethargy (d9-11); loss of appetite (d6-11); tremors (d11); facial edema (d10-11); animal succumbed in am of d11	Granulocytosis (d5); thrombocytopenia (d7,10,11); lymphopenia (d11); hyperglycemia (d10); AST > 2-fold ↑ (d7,10); AST > 3-fold ↑ (d11); CRP > 2-fold ↑ (d5,7); CRP > 4-fold ↑ (d10); CRP > 8-fold ↑ (d11)
C-3 (1)	F	None	None	Fever (d7); depression (d10); loss of appetite (d5-10); seizures (d10); animal succumbed in am of d10	Leukopenia (d7); granulocytosis (d5); lymphopenia (d7); hyperglycemia (d10); hypoalbuminemia (d10); ALT > 10-fold ↑ (d10); AST > 2-fold ↑ (d7); AST > 10-fold ↑ (d10); CRP > 3-fold ↑ (d3); CRP > 8-fold ↑ (d5); CRP > 4-fold ↑ (d7); CRP > 10-fold ↑ (d10)
C-4 (H ^c)	F	None	None	Depression (d8-12); loss of appetite (d6-12); lethargy (d8-12); mild rash (d12); facial edema (d12); animal succumbed in am of d12	Leukocytosis (d12); granulocytosis (d12); lymphopenia (d4,7); thrombocytopenia (d7,10,12); hypoalbuminemia (d12); ALT > 7-fold ↑ (d7); ALT > 10-fold ↑ (d12); AST > 10-fold ↑ (d10,12); ALP > 6-fold ↑ (d12); BUN > 2-fold ↑ (d12); GGT > 3-fold ↑ (d12); CRP > 2-fold ↑ (d7); CRP > 10-fold ↑ (d10,12)
C-5 (2)	M	None	None	Depression (d10-12); lethargy (d10-12); loss of appetite (d7-12); facial swelling (d11,12); testicular swelling (d12); paresis (d12); animal succumbed in am of d12	Lymphopenia (d3,7,10); thrombocytopenia (d7); hypoalbuminemia (d10,12); ALT > 3-fold ↑ (d10); ALT > 10-fold ↑ (d12); AST > 9-fold ↑ (d10); AST > 10-fold ↑ (d12); ALP > 2-fold ↑ (d12); CRP > 7-fold ↑ (d5); CRP > 3-fold ↑ (d7); CRP > 10-fold ↑ (d10,12)
C-6 (3)	M	None	None	Fever (d8); depression (d9-11); lethargy (d9-11); loss of appetite (d2-11); mild petechial rash (d11); facial edema (d11); seizures (d11); animal succumbed in am of d11	Leukopenia (d8); lymphopenia (d8,11); thrombocytopenia (d11); hyperglycemia (d11); hypoalbuminemia (d11); ALT > 3-fold ↑ (d11); AST > 10-fold ↑ (d10); CRP > 3-fold ↑ (d4); CRP > 10-fold ↑ (d11)
C-7 (4)	F	None	None	Fever (d8,11); depression (d10-15); lethargy (d12-15); anorexia (d5-15); facial edema (d12-15); tremors (d13-15); seizures (d15); animal succumbed in am of d15	Leukopenia (d8); lymphopenia (d4,8,11,15); thrombocytopenia (d4,8,11,15); hypoalbuminemia (d15); ALT > 7-fold ↑ (d15); AST > 2-fold ↑ (d11); AST > 10-fold ↑ (d15); CRP > 5-fold ↑ (d4); CRP > 3-fold ↑ (d11); CRP > 10-fold ↑ (d15)
C-8 (4)	F	None	None	Depression (d10); lethargy (d10); anorexia (d6-10); seizures (d10); animal succumbed in am of d10	Lymphopenia (d8); thrombocytopenia (d8,10); hypoalbuminemia (d10); ALT > 2-fold ↑ (d10); AST > 7-fold ↑ (d10); CRP > 4-fold ↑ (d4); CRP > 10-fold ↑ (d8,10)
C-9 (5)	M	None	None	Depression (d14-19); lethargy (d16-19); anorexia (d7-19); mild rash (d14,15); facial edema (d11-19); tremors (d16-19); paresis (d19); animal succumbed in am of d19	Granulocytosis (d19); lymphopenia (d9); thrombocytopenia (d9,19); hypoalbuminemia (d9,14,19); ALT > 3-fold ↑ (d9); ALT > 10-fold ↑ (d14,19); AST > 7-fold ↑ (d9,19); AST > 10-fold ↑ (d14); ALP > 4-fold ↑ (d19); CRP > 2-fold ↑ (d3); CRP > 4-fold ↑ (d6); CRP > 3-fold ↑ (d9); CRP > 5-fold ↑ (d14); CRP > 6-fold ↑ (d19)
C-10 (6)	M	None	None	Depression (d11-21); lethargy (d17-21); anorexia (d8-21); mild rash (d9-16); dyspnea (d21); paresis (d21); animal succumbed in am of d21	Leukocytosis (d12,15,21); granulocytosis (d12,15,21); lymphopenia (d6,9,21); thrombocytopenia (d6,9,12); hypoalbuminemia (d12,15,21); ALT > 3-fold ↑ (d6); ALT > 10-fold ↑ (d9,12,15); ALT > 5-fold ↑ (d21); AST > 2-fold ↑ (d6); AST > 10-fold ↑ (d9,12); AST > 4-fold ↑ (15); ALP > 2-fold ↑ (d9); ALP > 5-fold ↑ (d12); ALP > 4-fold ↑ (15,21); BUN > 2-fold ↑ (d12,15,21); GGT > 2-fold ↑ (d9,15); GGT > 3-fold ↑ (d12); CRP > 4-fold ↑ (d6); CRP > 6-fold ↑ (d9); CRP > 7-fold ↑ (d12); CRP > 3-fold ↑ (d21)
C-11 (7)	F	None	None	Depression (d12); lethargy (d12); loss of appetite (d11,12); seizures (d12); animal succumbed in am of d12	Thrombocytopenia (d8,11,12); hypoalbuminemia (d11,12); ALT > 5-fold ↑ (d8); ALT > 10-fold ↑ (d11,12); AST > 2-fold ↑ (d8); AST > 10-fold ↑ (d11,12); ALP > 2-fold ↑ (d11); ALP > 4-fold ↑ (d12); GGT > 2-fold ↑ (d12); CRP > 5-fold ↑ (d8); CRP > 10-fold ↑ (d11,12)

^a Experiment for cohort; see Methods for back challenge information

^bC = Control untreated animal

^cH= Historical control

Days after Lassa challenge are in parentheses. Fever is defined as a temperature more than 2.5°F over baseline or at least 1.3°F over baseline and ≥ 103.5F or 1.1°F over baseline and ≥ 104.0°F.

Mild rash: focal areas of petechiae covering less than 10% of the skin. Lymphopenia and thrombocytopenia are defined by a ≥35% drop in numbers of lymphocytes and platelets, respectively.

Leukocytosis and granulocytosis are defined by a two-fold or greater increase in numbers of white blood cells over base line. Hyperglycemia is defined as a two-fold or greater increase in levels of glucose. Hypoalbuminemia is defined by a ≥35% decrease in levels of albumin. (ALT) alanine aminotransferase, (ALP) alkaline phosphatase, (AST) aspartate aminotransferase, (BUN) blood urea nitrogen, (CRP), C-reactive protein, (GGT) gamma glutamyltransferase.

Supplementary Table 2. Clinical description and outcome of Lassa challenged and single huMAb treated NHPs

Subject No. ^(a)	Sex	MAb ^d	Treatment Regimen (Days)	Clinical illness	Clinical and gross pathology
^b STx-1 (2)	F	19.7E	0 and 5	Depression (13-15); loss of appetite (d9-15); lethargy (d14,15); mild rash (d14,15); facial edema (d13-15); animal succumbed in pm of d15	Leukopenia (d7,10); lymphopenia (d7,10); thrombocytopenia (d10); hyperglycemia (d15); hypoalbuminemia (d15); ALT > 10-fold ↑ (d15); AST > 2-fold ↑ (d10); AST > 10-fold ↑ (d15); ALP > 6-fold ↑ (15); GGT > 10-fold ↑ (d15); CRP > 4-fold ↑ (d7); CRP > 7-fold ↑ (d10); CRP > 10-fold ↑ (d15)
STx-2 (2)	M	19.7E	0 and 5	None	Lymphopenia (d7)
STx-3 (2)	M	19.7E	0 and 5	None	Thrombocytopenia (d15); CRP > 2-fold ↑ (d7,15)
STx-4 (2)	F	19.7E	0 and 5	Fever (d7, animal menstruating)	Lymphopenia (d7,15); thrombocytopenia (d15); CRP > 2-fold ↑ (d5); CRP > 3-fold ↑ (d7)
STx-5 (3)	M	37.2D	0, 4, and 8	None	None
STx-6 (3)	M	37.2D	0, 4, and 8	None	CRP > 3-fold ↑ (d11,30); CRP > 2-fold ↑ (d22)
STx-7 (3)	M	37.2D	0, 4, and 8	None	CRP > 4-fold ↑ (d22)
STx-8 (3)	M	37.2D	0, 4, and 8	None	CRP > 2-fold ↑ (d22)
STx-9 (4) ^e	M	37.2D	0, 4, and 8	None	None
STx-10 (4) ^c	M	37.2D	0, 4, and 8	None	None
STx-11 (4)	M	12.1F	0, 4, and 8	None	None
STx-12 (4)	M	12.1F	0, 4, and 8	None	Granulocytosis (d11); CRP > 3-fold ↑ (d8); CRP > 4-fold ↑ (d15)
STx-13 (4)	M	12.1F	0, 4, and 8	None	Lymphopenia (d8); CRP > 2-fold ↑ (d8,11)
STx-14 (4)	F	37.7H	0, 4, and 8	None	None
STx-15 (4)	F	37.7H	0, 4, and 8	None	ALT > 2-fold ↑ (d4)
STx-16 (4)	M	37.7H	0, 4, and 8	None	None
STx-17 (5)	F	8.9F	0, 4, and 8	None	Leukopenia (d4,8); lymphopenia (d4,8,11); thrombocytopenia (d11); hypoalbuminemia (d21,28); ALT > 4-fold ↑ (d11); ALT > 5-fold ↑ (d15); AST > 7-fold ↑ (d11); AST > 6-fold ↑ (d15); ALP > 2-fold ↑ (d11,15,21); ALP > 3-fold ↑ (d28); CRP > 5-fold ↑ (d8); CRP > 7-fold ↑ (d11,28); CRP > 4-fold ↑ (d15); CRP > 6-fold ↑ (d22)
STx-18 (5)	M	8.9F	0, 4, and 8	None	Lymphopenia (d8)
STx-19 (5)	M	8.9F	0, 4, and 8	None	Granulocytosis (d4,8,21,28); lymphopenia (d8)
STx-20 (5)	M	8.9F	0, 4, and 8	None	Granulocytosis (d4)

^a Experiment for cohort; see Methods for back challenge information

^bSTx = Single-huMAb treated animals.

^c Dose down cohort; different from all studies: 6 mg/Kg

Days after Lassa challenge are in parentheses. Fever is defined as a temperature more than 2.5°F over baseline or at least 1.3°F over baseline and ≥ 103.5°F or 1.1°F over baseline and ≥ 104.0°F. Mild rash: focal areas of petechiae covering less than 10% of the skin. Lymphopenia and thrombocytopenia are defined by a ≥35% drop in numbers of lymphocytes and platelets, respectively. Leukocytosis and granulocytosis are defined by a two-fold or greater increase in numbers of white blood cells over base line. Hyperglycemia is defined as a two-fold or greater increase in levels of glucose. Hypoalbuminemia is defined by a ≥35% decrease in levels of albumin. (ALT) alanine aminotransferase, (ALP) alkaline phosphatase, (AST) aspartate aminotransferase, (BUN) blood urea nitrogen, (CRP), C-reactive protein, (GGT) gamma glutamyltransferase.^d15 mg/Kg, unless otherwise noted

Supplementary Table 3. Percent binding of 37.2D, 12.1F, and 8.9F huMAbs to LASV GP Y150D mutant relative to wild type GP in FACS assays on HEK-293T cell surface-expressed viral glycoprotein

		Percent binding relative to wild type control (avg, N=3)		
MARM	Epitope region	37.2D	12.1F	8.9F
Y150D	GPC-C	216	116	0

Supplementary Table 4. Clinical description and outcome of Lassa challenged and cocktail huMAb treated NHPs

Subject No. (^a)	Sex	MAb ^d	Treatment Regimen (Days)	Clinical illness	Clinical and gross pathology
^b CTx-1 (3)	M	19.7E + 37.2D	0, 4, and 8	None	Granulocytosis (d15)
CTX-2 (3)	M	19.7E + 37.2D	0, 4, and 8	None	None
CTX-3 (3)	M	19.7E + 37.2D	0, 4, and 8	None	None
CTX-4 (3)	F	19.7E + 37.2D	0, 4, and 8	None	None
CTX-5 (5)	F	8.9F+12.1F+37.2D	3, 6, and 9	None	Granulocytosis (d3); lymphopenia (d6); CRP > 3-fold ↑ (d3,6)
CTX-6 (5)	M	8.9F+12.1F+37.2D	3, 6, and 9	None	Granulocytosis (d14); Lymphopenia (d3,6); CRP > 2-fold ↑ (d3)
CTX-7 (5)	M	8.9F+12.1F+37.2D	3, 6, and 9	None	Leukocytosis (d3,21); granulocytosis (d3,21); ALT > 2-fold ↑ (d3); CRP > 4-fold ↑ (d3)
CTX-8 (5)	M	8.9F+12.1F+37.2D	3, 6, and 9	None	None
CTx-9 (6)	M	8.9F+12.1F+37.2D	6, 9, and 12	Fever (d6)	Granulocytosis (d21); lymphopenia (d6); thrombocytopenia (d6); CRP > 4-fold ↑ (d6); CRP > 5-fold ↑ (d9)
CTx-10 (6)	M	8.9F+12.1F+37.2D	6, 9, and 12	Depression (d7); anorexia (d5-11);	Lymphopenia (d6,9); thrombocytopenia (d6,9); ALP > 2-fold ↑ (d12)
CTx-11 (6)	F	8.9F+12.1F+37.2D	6, 9, and 12	Anorexia (d5-14)	Leukopenia (d6,9); lymphopenia (d6,9); thrombocytopenia (d6,9,12); CRP > 5-fold ↑ (d6); CRP > 3-fold ↑ (d9)
CTx-12 (6)	M	8.9F+12.1F+37.2D	6, 9, and 12	Fever (d6,9)	Leukocytosis (d21); granulocytosis (d21); lymphopenia (d6,9); thrombocytopenia (d9); CRP > 5-fold ↑ (d6); CRP > 3-fold ↑ (d9)
CTx-13 (7)	M	8.9F+12.1F+37.2D	8, 11, and 14	None	Leukocytosis (d11,14,21,30); ALT > 3-fold ↑ (d14); ALT > 5-fold ↑ (d11); AST > 2-fold ↑ (d8,11)
CTx-14 (7)	M	8.9F+12.1F+37.2D	8, 11, and 14	None	Granulocytosis (d8); ALT > 2-fold ↑ (d11); AST > 2-fold ↑ (d8); CRP > 5-fold ↑ (d8)
CTx-15 (7)	F	8.9F+12.1F+37.2D	8, 11, and 14	Anorexia (d8-d12)	Leukocytosis (d14); granulocytosis (d11,14); thrombocytopenia (d8,11); ALT > 4-fold ↑ (d14); ALT > 5-fold ↑ (d8); ALT > 10-fold ↑ (d11); AST > 2-fold ↑ (d14); AST > 5-fold ↑ (d11); AST > 10-fold ↑ (d8); ALP > 2-fold ↑ (d30); ALP > 3-fold ↑ (d21); ALP > 5-fold ↑ (d8,14); ALP > 10-fold ↑ (d11); CRP > 5-fold ↑ (d11); CRP > 10-fold ↑ (d8)
CTx-16 (7)	M	8.9F+12.1F+37.2D	8, 11, and 14	Fever (d8); mild depression (d10)	Lymphopenia (d8); thrombocytopenia (d8,11); ALT > 3-fold ↑ (d8,14); ALT > 5-fold ↑ (d11); AST > 2-fold ↑ (d8); CRP > 3-fold ↑ (d11); CRP > 10-fold ↑ (d8)
CTx-17 (7)	M	8.9F+12.1F+37.2D	8, 11, and 14	Mild depression (d9,10)	Leukocytosis (d11,14); granulocytosis (d8,14); lymphopenia (d8); thrombocytopenia (d8,11); hypoalbuminemia (d11); ALT > 2-fold ↑ (d21); ALT > 5-fold ↑ (d14); ALT > 10-fold ↑ (d8,11); AST > 5-fold ↑ (d14); AST > 10-fold ↑ (d8,11); ALP > 2-fold ↑ (d8); > 5-fold ↑ (d11,14); CRP > 3-fold ↑ (d11); CRP > 10-fold ↑ (d8)

^a Experiment for cohort; see Methods for back challenge information

^bCTX = Cocktail huMAb treated animals.

Days after Lassa challenge are in parentheses. Fever is defined as a temperature more than 2.5°F over baseline or at least 1.3°F over baseline and ≥ 103.5°F or 1.1°F over baseline and ≥ 104.0°F. Mild rash: focal areas of petechiae covering less than 10% of the skin. Lymphopenia and thrombocytopenia are defined by a ≥35% drop in numbers of lymphocytes and platelets, respectively. Leukocytosis and granulocytosis are defined by a two-fold or greater increase in numbers of white blood cells over base line. Hyperglycemia is defined as a two-fold or greater increase in levels of glucose. Hypoalbuminemia is defined by a ≥35% decrease in levels of albumin. (ALT) alanine aminotransferase, (ALP) alkaline phosphatase, (AST) aspartate aminotransferase, (BUN) blood urea nitrogen, (CRP), C-reactive protein, (GGT) gamma glutamyltransferase.

^d15 mg/Kg, unless otherwise noted

Supplementary Table 5. Tissue Severity H&E and IHC scores and RT-qPCR load for CTx 8.9F+12.1F+37.2D groups

Subject No. ^(a)	Treatment Regimen (Days)	^b H&E Liver / Spleen / Brain	^c IHC GP Liver / Spleen / Brain	^d RT-qPCR Liver / Spleen ^(e) / Brain
^f C-9 (5)	Control	3 / 2 / 1	3 / 2 / 1	9 / 6 (6) / 8
^g CTx-5 (5)	3, 6, and 9	1 / 0 / 0	2 / 1 / 1	6 / 7 (<LoD) / 5
CTx-6 (5)	3, 6, and 9	0 / 0 / 0	1 / 1 / 1	5 / 6 (3) / 5
CTx-7 (5)	3, 6, and 9	0 / 0 / 0	1 / 1 / 1	<LoD / 5 (<LoD) / 5
CTx-8 (5)	3, 6, and 9	0 / 0 / 0	0 / 0 / 0	<LoD / 5 (<LoD) / <LoD
C-10 (6)	Control	0 / 0 / 0	0 / 1 / 1	7 / 8 / 8
CTx-9 (6)	6, 9, and 12	0 / 0 / 0	0 / 0 / 0	<LoD / 6 / 5
CTx-10 (6)	6, 9, and 12	0 / 0 / 1	0 / 0 / 0	6 / 7 / 5
CTx-11 (6)	6, 9, and 12	0 / 0 / 1	0 / 0 / 0	6 / 7 / 6
CTx-12 (6)	6, 9, and 12	0 / 0 / 1	0 / 0 / 0	7 / 7 / <LoD
C-11 (7)	Control	3 / 2 / 1	3 / 2 / 1	11 / 11 / 10
CTx-13 (7)	8, 11, and 14	0 / 0 / 0	0 / 0 / 0	8 / 9 / 9
CTx-14 (7)	8, 11, and 14	0 / 0 / 0	0 / 0 / 0	<LoD / 7 / <LoD
CTx-15 (7)	8, 11, and 14	1 / 0 / 0	0 / 0 / 0	8 / 9 / 8
CTx-16 (7)	8, 11, and 14	0 / 0 / 0	0 / 0 / 0	7 / 9 / 7
CTx-17 (7)	8, 11, and 14	0 / 0 / 0	0 / 0 / 0	8 / 10 / 9

^a Experiment for cohort; see Methods for back challenge information

^b Severity scoring was awarded for each H&E stained tissue based on a 0 to 4 scale. A score of 0 indicated no lesions, 1 minimal lesions where less than 25% of the tissue was affected, 2 mild lesions where 26-50% of the tissue was affected, 3 moderate lesions were 51-75% of the tissue was affected, 4 marked lesions where 76-100% of the tissue was affected.


^c Severity scoring was awarded for IHC immunopositivity was awarded for each tissue section, 0 indicated no immunolabeling, 1 indicated less than 25% immunolabeling, 2 indicated 26-50% immunolabeling, 3 indicated 51-75% immunolabeling, 4 indicated 76-100% immunolabeling.

^d Log₁₀ of RNA GEq in one gram of tissue. LoD = limit of detection


^e Bold = Log₁₀ of PFU/g of infectious virus isolated from spleen. LoD = limit of detection

^fC = Control untreated animal


^gCTx = Cocktail huMAb treated animals at 15 mg/Kg each huMAb




Supplementary Figure 1. Viral load in cynomolgus macaques treated with single LASV huMAbs or untreated. **a**, control cohort **b**, 19.7E and 37.7H cohorts and **c**, 37.2D, 12.1F, and 8.9F cohorts graphs depicting circulating virus load for each cohort as measured by RT-qPCR for LASV genome equivalents (GEq)/mL with the lower limit of detection of 1×10^4 GEq/mL. Error bars are +/- standard deviation from the mean. Limit of detection depicted as dashed line on graphs.




Supplementary Figure 2. LASV 8.9F(e) neutralized by huMAb cocktail. Percent infectivity of the challenge LASV (black) or the 8.9F escape LASV, LASV 8.9F(e) (orange), in the presence of 100 μ g or 50 μ g of a single huMAb 8.9F, 12.1F, or 37.2D or a cocktail (CTx) of all three huMAbs.




Supplementary Figure 3. Viral load in cynomolgus macaques treated with 8.9F/12.1F/37.2D cocktail of LASV huMAbs or untreated. **a**, control cohort and **b**, 8.9F/12.1F/37.2D +3, +6, and +8 cohort graphs depicting circulating virus load for each cohort as measured by RT-qPCR for LASV genome equivalents (GEq)/mL with the lower limit of detection of 1×10^4 GEq/mL. Error bars are +/- standard deviation from the mean. Limit of detection depicted as dashed line on graphs.




Supplementary Figure 4. Viral load in cynomolgus macaques treated with 8.9F/12.1F/37.2D combination therapy of LASV huMAbs. **a** +3 CTx cohort, **c** +6 CTx cohort, and **e** +8 CTx cohort, virus load for each cohort as measured by plaque forming units (PFU) /mL with the lower limit of detection of 15 PFU/mL. **b** +3 CTx cohort, **d** +6 CTx cohort, and **f** +8 CTx cohort, circulating virus load for each cohort as measured by RT-qPCR for LASV genome equivalents (GEq)/mL with the lower limit of detection of 1×10^4 GEq/mL. CTx-cocktail huMAb treatment group. Error bars are +/- standard deviation from the mean. Limit of detection depicted as dashed line on graphs.



Supplementary Figure 5. Cynomolgus macaque humoral response to LASV challenge. **a,** **b, c, and d;** Zalgen ELISA assay for anti-LASV NP IgG with absorbance readings at 450nm. C- Control. CTx- cocktail huMAb treatment group. Error bars are s.d.



Supplementary Figure 6. Lack of LASV histopathology and antigen in delayed treatment cynomolgus macaques. Representative histopathology images for spleen (**a, g, m**), liver (**c, i, o**), and frontal cortex of brain (**e, k, q**) from the control group (C-11/day 12), CTx +6 group (CTx-12/study endpoint), and CTx +8 group (CTx-17/study endpoint). Representative immunohistochemistry images for spleen (**b, h, n**), liver (**d, j, p**), and frontal cortex of brain (**f, l, r**) from the control group (C-11/day 12), CTx +6 group (CTx-12/study endpoint), and CTx +8 group (CTx-17/study endpoint). **k**, mild perivascular cuffing representative of inflammation located in the middle of the panel. **b, d, f**, LASV immunolabeling in tissues from C-11.



Supplementary Figure 7. Lack of LASV histopathology in day +3 delayed treatment

cynomolgus macaques. Representative histopathology images for spleen (**a, g, m**), liver (**c, i, o**), and frontal cortex of brain (**e, k, q**) from the control group (C-9/day 19), CTx +3 group (CTx-5/study endpoint), and CTx +3 group (CTx-8/study endpoint). Representative immunohistochemistry images for spleen (**b, h, n**), liver (**d, j, p**), and frontal cortex of brain (**f, l, r**) from the control group (C-9/day 19), CTx +3 group (CTx-5/study endpoint), and CTx +3 group (CTx-8/study endpoint). **e**, mild perivascular cuffing representative of inflammation located in the middle of the panel. **b, d, f**, marked LASV immunolabeling in tissues from C-9. **h, j, l**, marked LASV immunolabeling in tissues from CTx-5.